PERNYATAAN FDA TERKAIT JADWAL VAKSIN COVID-19   Dua vaksin mRNA yang berbeda menunjukkan efektivitas luar biasa, yaitu sekitar 95% dalam mencegah penyakit COVID-19 pada orang dewasa. Saat penerima vaksin putaran pertama memenuhi persyaratan untuk menerima dosis yang kedua, FDA ingin mengingatkan…

PIC/S ANEKS 3 (PEMBUATAN RADIOFARMAKA) – GLOSARIUM ANEKS 3 NO VERSI ASLI VERSI TERJEMAHAN Preparation: handling and radiolabelling of kits with radionuclide eluted from generators or radioactive precursors within a hospital. Kits, generators and precursors should have a marketing authorisation or a…

PIC/S ANEKS 3 (PEMBUATAN RADIOFARMAKA) – DISTRIBUSI NO VERSI ASLI VERSI TERJEMAHAN 51 Distribution of the finished product under controlled conditions, before all appropriate test results are available, is acceptable for radiopharmaceuticals, providing the product is not administered by the receiving institute…

PIC/S ANEKS 3 (PEMBUATAN RADIOFARMAKA) – SAMPEL REFERENSI DAN PERTINGGAL NO VERSI ASLI VERSI TERJEMAHAN 48 For radiopharmaceuticals sufficient samples of each batch of bulk formulated product should be retained for at least six months after expiry of the finished medicinal product…

PIC/S ANEKS 3 (PEMBUATAN RADIOFARMAKA) – PENGAWASAN MUTU NO VERSI ASLI VERSI TERJEMAHAN 39 Some radiopharmaceuticals may have to be distributed and used on the basis of an assessment of batch documentation and before all chemical and microbiology tests have been completed.

PIC/S ANEKS 3 (PEMBUATAN RADIOFARMAKA) – PRODUKSI NO VERSI ASLI VERSI TERJEMAHAN 34 Production of different radioactive products in the same working area (i.e. hot-cell, LAF unit), at the same time should be avoided in order to minimise the risk of cross-contamination…